A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction (VALOR)
Latest Information Update: 15 Jun 2025
At a glance
- Drugs Vericiguat (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms VALOR
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 12 Dec 2024 Planned End Date changed from 30 Apr 2030 to 15 Apr 2032.
- 12 Dec 2024 Planned primary completion date changed from 30 Apr 2030 to 15 Apr 2032.
- 09 May 2023 Planned initiation date changed from 15 Mar 2023 to 19 May 2023.